Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 0.66 |
| ▸ | CCNA2 | P20248 | 10/20 | 0.66 |
| ▸ | CDK2 | P24941 | 10/20 | 0.66 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930949 | 0.93 | CHEK1 (0.66) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931017 | 0.93 | CHEK1 (0.66) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL7886620 | 0.90 | CHEK1 (0.62) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL6891872 | 0.90 | CHEK1 (0.62) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL10239436 | 0.90 | CHEK1 (0.62) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931004 | 0.90 | CHEK1 (0.62) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11930998 | 0.90 | CHEK1 (0.62) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL6891866 | 0.88 | CHEK1 (0.51) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931000 | 0.88 | CHEK1 (0.62) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931482 | 0.88 | CHEK1 (0.60) | CHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.